The US measles elimination status is under review as the country confronts its largest resurgence in more than three decades, but the Centers for Disease Control and Prevention does not plan to fundamentally change its response if the designation is lost. CDC Director Erica Schwartz told Reuters the agency would continue working with states and promoting vaccination while regional health experts assess whether transmission has become continuous.
The review comes during the country’s largest measles resurgence in more than three decades. CDC surveillance data recorded 5,182 cases through November 5, with 43 outbreaks reported during 2026. The agency says 96% of cases have been associated with outbreaks, indicating that transmission has been concentrated in connected clusters rather than appearing as isolated imported infections alone.
Measles elimination does not mean a country has no cases. It means the virus is no longer spreading continuously through an endemic chain of transmission. Imported cases can still occur, and local outbreaks can still happen, but public-health authorities are able to trace and interrupt those chains before they become sustained transmission of the same virus lineage for a year or more.
The distinction is important because a country can record a large number of cases without automatically losing elimination status. The determining question is whether transmission has continued uninterrupted for at least 12 months. The Pan American Health Organization has convened its regional verification commission to examine the evidence from countries across the Americas, including the United States. The commission’s review is taking place from November 10 to 13, with a decision expected early next week, according to Schwartz’s interview with Reuters.
The United States was certified as having eliminated measles in 2000 after years of vaccination and outbreak control. Losing that status would be a public-health marker that sustained transmission has re-established itself. It would not mean the vaccine has stopped working, that every state has endemic measles, or that the federal government has automatically adopted a new set of restrictions.
Canada lost its measles elimination status in 2025 after the same virus lineage circulated continuously for 12 months. The regional review is therefore examining a wider picture of transmission across the Americas. A country-level determination for the United States would depend on the epidemiological record and the commission’s assessment of whether the required period of continuous transmission has been met.
Schwartz said the CDC would continue working with state health departments, helping them communicate risks and emphasizing the measles, mumps, and rubella vaccine. Her position is that the operational response would remain broadly the same whether or not the status changes. That means local outbreak investigations, contact tracing, vaccination clinics, public information, and support for health departments would remain central.
The CDC’s latest published count, covering cases through November 5, lists 5,182 infections in 2026. That is more than twice the 2,289 cases recorded during 2025. The agency has reported 43 outbreaks this year, compared with 48 in 2025. The fact that the number of outbreaks is lower while the case count is higher suggests that some clusters have been substantially larger or have persisted longer, rather than the disease being evenly distributed across the country.
Measles spreads through the air and can remain infectious in a room after an infected person has left. The virus is especially dangerous for infants too young to be vaccinated, people with weakened immune systems, and those who have not received the recommended doses. Complications can include pneumonia, inflammation of the brain, and, in rare cases, death. The risk is not limited to the person who first brings the virus into a community; a single infection can produce a chain of cases when vaccination coverage is low.
The CDC says two doses of the MMR vaccine are about 97% effective at preventing measles, while one dose is about 93% effective. The vaccine has been used for decades and remains the main tool for preventing outbreaks. The challenge is not a loss of vaccine effectiveness but gaps in coverage, delayed vaccination, misinformation, and the difficulty of reaching communities where access or confidence is low.
Outbreaks have affected communities with lower vaccination rates, including some religious and geographically connected groups. That should not be turned into a blanket description of any faith or community. Vaccination levels vary widely within groups, and public health teams need local data to identify where transmission is occurring. The most useful response is to provide accurate information and accessible vaccination, rather than stigmatize entire populations.
Schwartz told Reuters that the CDC would continue to work with states and reinforce the message that vaccination is the most effective prevention. The agency’s role includes surveillance, laboratory support, guidance for clinicians, and assistance to state and local authorities. State health departments remain responsible for many of the practical steps that determine whether an outbreak is contained.
The regional verification process examines more than the headline case count. Experts consider whether the same measles virus lineage has been circulating continuously, whether cases can be linked to imported infections, the quality of laboratory evidence, the effectiveness of surveillance, and the capacity of national immunization programs to respond. The commission’s work is technical: it reviews evidence and makes recommendations rather than issuing a political judgment about a government.
The timing is significant because the United States has recorded thousands of cases across multiple outbreaks since early 2025. Public health experts have warned that sustained chains of transmission could meet the threshold for loss of elimination status. The CDC has not said that a final determination has already been made. Schwartz told Reuters she expected the PAHO decision by early next week.
A change in status would carry reputational and regional consequences. The United States has long presented measles elimination as evidence that high vaccination coverage and coordinated surveillance can control a highly contagious disease. Losing the designation would signal that transmission has persisted beyond the time limit used by global health authorities. It could also sharpen scrutiny of school vaccination requirements, state immunization policies, and the ability of local health systems to respond to outbreaks.
But the practical response would not depend on a label. A child exposed to measles needs the same clinical assessment whether or not the country retains elimination status. A school with an outbreak still needs to identify susceptible students and follow public health advice. A hospital still needs infection-control procedures to protect patients and staff. The status decision is a measure of transmission history, not a substitute for local outbreak management.
Parents and caregivers should check whether children have received the recommended MMR doses and consult healthcare professionals if vaccination records are incomplete. People planning international travel should review the advice that applies to their destination and age group. Infants, pregnant people, and those with weakened immune systems may need tailored guidance after exposure, so public health officials recommend seeking medical advice rather than relying on general social media posts.
Clinicians and local health departments will be watching for new clusters, the genetic links between cases, and evidence that transmission is continuing in the same communities. Laboratory confirmation helps distinguish measles from illnesses with similar symptoms and allows epidemiologists to trace whether cases belong to an existing chain. That work is particularly important when a virus is circulating across state borders or when infected travellers move between countries.
The CDC’s position is that its response will continue regardless of the PAHO decision. The agency will keep supporting state investigations, encouraging vaccination and providing technical guidance. If the United States loses elimination status, the change will formalize a problem that health officials are already trying to contain; it will not create a new virus or make the MMR vaccine less effective.
The review is therefore a test of how far measles transmission has become established, not a referendum on whether vaccination works. The next decision will depend on epidemiological evidence gathered across the region. Until that assessment is published, the most reliable measure for families remains vaccination coverage and the local advice issued by their health department.